Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)
A total of 192 pediatric patients, median age 8.6 years, with high‐risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo‐HSCT) using post‐transplantation cyclophosphamide (PT‐Cy), or ex vivo T cell‐depleted (TCD) graft platforms, from January 1999 to December 201...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2020-01, Vol.95 (1), p.28-37 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | 1 |
| container_start_page | 28 |
| container_title | American journal of hematology |
| container_volume | 95 |
| creator | Pérez‐Martínez, Antonio Ferreras, Cristina Pascual, Antonia Gonzalez‐Vicent, Marta Alonso, Laura Badell, Isabel Fernández Navarro, José María Regueiro, Alexandra Plaza, Mercedes Pérez Hurtado, Jose María Benito, Ana Beléndez, Cristina Couselo, José Miguel Fuster, José Luis Díaz‐Almirón, Mariana Bueno, David Mozo, Yasmina Marsal, Julia Gómez López, Alicia Sisinni, Luisa Heredia, Cristina Díaz Díaz, Miguel Ángel |
| description | A total of 192 pediatric patients, median age 8.6 years, with high‐risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo‐HSCT) using post‐transplantation cyclophosphamide (PT‐Cy), or ex vivo T cell‐depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers in Spain. Some 41 patients received an unmanipulated graft followed by PT‐Cy for graft‐vs‐host disease (GvHD) prophylaxis. A total of 151 patients were transplanted with CD3‐depleted peripheral blood stem cells (PBSCs) by either CD34+ selection, CD3+CD19+ depletion, TCRαβ+CD19+ depletion or CD45RA+ depletion, added to CD34+ selection for GvHD prophylaxis. The PBSCs were the only source in patients following ex vivo TCD haplo‐HSCT; bone marrow was the source in 9 of 41 patients following PT‐CY haplo‐HSCT. Engraftment was achieved in 91.3% of cases. A donor younger than 30 years, and the development of chronic GvHD were positive factors influencing survival, whereas positive minimal residual disease (MRD) before transplant and lymphoid disease were negative factors. The probability of relapse increased with lymphoid malignancies, a donor killer‐cell immunoglobulin‐like receptor (KIR) haplotype A and positive MRD pretransplant. No difference was found in overall survival, disease‐free survival or relapse incidence between the two platforms. Relapse is still of concern in both platforms, and it should be the focus of future efforts. In conclusion, both platforms for haplo‐HSCT were effective and could be utilized depending on the comfort level of the center. |
| doi_str_mv | 10.1002/ajh.25661 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2307154203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2323112597</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-a8aa5d2f4387a48975b6504bfcb0ba311869b4140eb2b30779e793983ae19f033</originalsourceid><addsrcrecordid>eNp1kstuEzEUhqcIRENhwQsgS2yaRVp7PFd2UdUmoEIXlPXoeOZMx4ln7Noeoux4hD4jT4KTFCRuK5_F5-9c9EfRa0bPGKXxOay6szjNMvYkmjBaZrMiS-On0YTyjIWalsfRC-dWlDKWFPR5dMxZFqcszydHR0swSssGBy9rUMRbGJxRMHjwUg9EDqSTd933bw9WujUx2EjwVtZE4bjGXsI7MicWvdXOYO3lVyS17g1Y2NcwgNo66UhQCexAtUS3xHdIPhsYpOvIRtu1HO7IwurRkFZbIvSApAdr9eZf49SdVI3FgZwuLm8_3nyahibNb8qFHY3eqzrswWujJYbt_pLtBMvpy-hZC8rhq8f3JPpydXl7sZxd3yzeX8yvZzUvCjaDAiBt4jbhRQ5JUeapyFKaiLYWVABnrMhKkbCEoogFp3leYl7ysuCArGwp5yfR6cFrrL4f0fmql65GFeZBPboqDp9YmsR79O0f6EqPNpxyR8WhV5yWeaCmB6oOx3cW28pYGe62rRitdrmoQi6qfS4C--bROIoem1_kzyAE4PwAbKTC7f9N1fzD8qD8AYybxsI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2323112597</pqid></control><display><type>article</type><title>Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><source>Wiley Online Library Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Pérez‐Martínez, Antonio ; Ferreras, Cristina ; Pascual, Antonia ; Gonzalez‐Vicent, Marta ; Alonso, Laura ; Badell, Isabel ; Fernández Navarro, José María ; Regueiro, Alexandra ; Plaza, Mercedes ; Pérez Hurtado, Jose María ; Benito, Ana ; Beléndez, Cristina ; Couselo, José Miguel ; Fuster, José Luis ; Díaz‐Almirón, Mariana ; Bueno, David ; Mozo, Yasmina ; Marsal, Julia ; Gómez López, Alicia ; Sisinni, Luisa ; Heredia, Cristina Díaz ; Díaz, Miguel Ángel</creator><creatorcontrib>Pérez‐Martínez, Antonio ; Ferreras, Cristina ; Pascual, Antonia ; Gonzalez‐Vicent, Marta ; Alonso, Laura ; Badell, Isabel ; Fernández Navarro, José María ; Regueiro, Alexandra ; Plaza, Mercedes ; Pérez Hurtado, Jose María ; Benito, Ana ; Beléndez, Cristina ; Couselo, José Miguel ; Fuster, José Luis ; Díaz‐Almirón, Mariana ; Bueno, David ; Mozo, Yasmina ; Marsal, Julia ; Gómez López, Alicia ; Sisinni, Luisa ; Heredia, Cristina Díaz ; Díaz, Miguel Ángel</creatorcontrib><description>A total of 192 pediatric patients, median age 8.6 years, with high‐risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo‐HSCT) using post‐transplantation cyclophosphamide (PT‐Cy), or ex vivo T cell‐depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers in Spain. Some 41 patients received an unmanipulated graft followed by PT‐Cy for graft‐vs‐host disease (GvHD) prophylaxis. A total of 151 patients were transplanted with CD3‐depleted peripheral blood stem cells (PBSCs) by either CD34+ selection, CD3+CD19+ depletion, TCRαβ+CD19+ depletion or CD45RA+ depletion, added to CD34+ selection for GvHD prophylaxis. The PBSCs were the only source in patients following ex vivo TCD haplo‐HSCT; bone marrow was the source in 9 of 41 patients following PT‐CY haplo‐HSCT. Engraftment was achieved in 91.3% of cases. A donor younger than 30 years, and the development of chronic GvHD were positive factors influencing survival, whereas positive minimal residual disease (MRD) before transplant and lymphoid disease were negative factors. The probability of relapse increased with lymphoid malignancies, a donor killer‐cell immunoglobulin‐like receptor (KIR) haplotype A and positive MRD pretransplant. No difference was found in overall survival, disease‐free survival or relapse incidence between the two platforms. Relapse is still of concern in both platforms, and it should be the focus of future efforts. In conclusion, both platforms for haplo‐HSCT were effective and could be utilized depending on the comfort level of the center.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.25661</identifier><identifier>PMID: 31625177</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Bone marrow ; Bone marrow transplantation ; Bone Marrow Transplantation - methods ; Bone Marrow Transplantation - mortality ; CD19 antigen ; CD3 antigen ; CD34 antigen ; CD45RA antigen ; Child ; Comparative analysis ; Cyclophosphamide ; Cyclophosphamide - therapeutic use ; Female ; Graft Survival ; Graft vs Host Disease - prevention & control ; Graft-versus-host reaction ; Hematologic Neoplasms - therapy ; Hematology ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic Stem Cell Transplantation - mortality ; Hematopoietic stem cells ; Humans ; Leukemia - mortality ; Leukemia - therapy ; Lymphocyte Depletion ; Lymphocytes T ; Male ; Minimal residual disease ; Pediatrics ; Pediatrics - methods ; Peripheral blood ; Prophylaxis ; Recurrence ; Retrospective Studies ; Spain ; Stem cell transplantation ; Survival Analysis ; T cell receptors ; Transplantation, Haploidentical ; Transplants & implants</subject><ispartof>American journal of hematology, 2020-01, Vol.95 (1), p.28-37</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><rights>2020 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-a8aa5d2f4387a48975b6504bfcb0ba311869b4140eb2b30779e793983ae19f033</citedby><cites>FETCH-LOGICAL-c3881-a8aa5d2f4387a48975b6504bfcb0ba311869b4140eb2b30779e793983ae19f033</cites><orcidid>0000-0002-6436-9195</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.25661$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.25661$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31625177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pérez‐Martínez, Antonio</creatorcontrib><creatorcontrib>Ferreras, Cristina</creatorcontrib><creatorcontrib>Pascual, Antonia</creatorcontrib><creatorcontrib>Gonzalez‐Vicent, Marta</creatorcontrib><creatorcontrib>Alonso, Laura</creatorcontrib><creatorcontrib>Badell, Isabel</creatorcontrib><creatorcontrib>Fernández Navarro, José María</creatorcontrib><creatorcontrib>Regueiro, Alexandra</creatorcontrib><creatorcontrib>Plaza, Mercedes</creatorcontrib><creatorcontrib>Pérez Hurtado, Jose María</creatorcontrib><creatorcontrib>Benito, Ana</creatorcontrib><creatorcontrib>Beléndez, Cristina</creatorcontrib><creatorcontrib>Couselo, José Miguel</creatorcontrib><creatorcontrib>Fuster, José Luis</creatorcontrib><creatorcontrib>Díaz‐Almirón, Mariana</creatorcontrib><creatorcontrib>Bueno, David</creatorcontrib><creatorcontrib>Mozo, Yasmina</creatorcontrib><creatorcontrib>Marsal, Julia</creatorcontrib><creatorcontrib>Gómez López, Alicia</creatorcontrib><creatorcontrib>Sisinni, Luisa</creatorcontrib><creatorcontrib>Heredia, Cristina Díaz</creatorcontrib><creatorcontrib>Díaz, Miguel Ángel</creatorcontrib><title>Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>A total of 192 pediatric patients, median age 8.6 years, with high‐risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo‐HSCT) using post‐transplantation cyclophosphamide (PT‐Cy), or ex vivo T cell‐depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers in Spain. Some 41 patients received an unmanipulated graft followed by PT‐Cy for graft‐vs‐host disease (GvHD) prophylaxis. A total of 151 patients were transplanted with CD3‐depleted peripheral blood stem cells (PBSCs) by either CD34+ selection, CD3+CD19+ depletion, TCRαβ+CD19+ depletion or CD45RA+ depletion, added to CD34+ selection for GvHD prophylaxis. The PBSCs were the only source in patients following ex vivo TCD haplo‐HSCT; bone marrow was the source in 9 of 41 patients following PT‐CY haplo‐HSCT. Engraftment was achieved in 91.3% of cases. A donor younger than 30 years, and the development of chronic GvHD were positive factors influencing survival, whereas positive minimal residual disease (MRD) before transplant and lymphoid disease were negative factors. The probability of relapse increased with lymphoid malignancies, a donor killer‐cell immunoglobulin‐like receptor (KIR) haplotype A and positive MRD pretransplant. No difference was found in overall survival, disease‐free survival or relapse incidence between the two platforms. Relapse is still of concern in both platforms, and it should be the focus of future efforts. In conclusion, both platforms for haplo‐HSCT were effective and could be utilized depending on the comfort level of the center.</description><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone Marrow Transplantation - methods</subject><subject>Bone Marrow Transplantation - mortality</subject><subject>CD19 antigen</subject><subject>CD3 antigen</subject><subject>CD34 antigen</subject><subject>CD45RA antigen</subject><subject>Child</subject><subject>Comparative analysis</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Graft Survival</subject><subject>Graft vs Host Disease - prevention & control</subject><subject>Graft-versus-host reaction</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic Stem Cell Transplantation - mortality</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Leukemia - mortality</subject><subject>Leukemia - therapy</subject><subject>Lymphocyte Depletion</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Minimal residual disease</subject><subject>Pediatrics</subject><subject>Pediatrics - methods</subject><subject>Peripheral blood</subject><subject>Prophylaxis</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Spain</subject><subject>Stem cell transplantation</subject><subject>Survival Analysis</subject><subject>T cell receptors</subject><subject>Transplantation, Haploidentical</subject><subject>Transplants & implants</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kstuEzEUhqcIRENhwQsgS2yaRVp7PFd2UdUmoEIXlPXoeOZMx4ln7Noeoux4hD4jT4KTFCRuK5_F5-9c9EfRa0bPGKXxOay6szjNMvYkmjBaZrMiS-On0YTyjIWalsfRC-dWlDKWFPR5dMxZFqcszydHR0swSssGBy9rUMRbGJxRMHjwUg9EDqSTd933bw9WujUx2EjwVtZE4bjGXsI7MicWvdXOYO3lVyS17g1Y2NcwgNo66UhQCexAtUS3xHdIPhsYpOvIRtu1HO7IwurRkFZbIvSApAdr9eZf49SdVI3FgZwuLm8_3nyahibNb8qFHY3eqzrswWujJYbt_pLtBMvpy-hZC8rhq8f3JPpydXl7sZxd3yzeX8yvZzUvCjaDAiBt4jbhRQ5JUeapyFKaiLYWVABnrMhKkbCEoogFp3leYl7ysuCArGwp5yfR6cFrrL4f0fmql65GFeZBPboqDp9YmsR79O0f6EqPNpxyR8WhV5yWeaCmB6oOx3cW28pYGe62rRitdrmoQi6qfS4C--bROIoem1_kzyAE4PwAbKTC7f9N1fzD8qD8AYybxsI</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Pérez‐Martínez, Antonio</creator><creator>Ferreras, Cristina</creator><creator>Pascual, Antonia</creator><creator>Gonzalez‐Vicent, Marta</creator><creator>Alonso, Laura</creator><creator>Badell, Isabel</creator><creator>Fernández Navarro, José María</creator><creator>Regueiro, Alexandra</creator><creator>Plaza, Mercedes</creator><creator>Pérez Hurtado, Jose María</creator><creator>Benito, Ana</creator><creator>Beléndez, Cristina</creator><creator>Couselo, José Miguel</creator><creator>Fuster, José Luis</creator><creator>Díaz‐Almirón, Mariana</creator><creator>Bueno, David</creator><creator>Mozo, Yasmina</creator><creator>Marsal, Julia</creator><creator>Gómez López, Alicia</creator><creator>Sisinni, Luisa</creator><creator>Heredia, Cristina Díaz</creator><creator>Díaz, Miguel Ángel</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6436-9195</orcidid></search><sort><creationdate>202001</creationdate><title>Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)</title><author>Pérez‐Martínez, Antonio ; Ferreras, Cristina ; Pascual, Antonia ; Gonzalez‐Vicent, Marta ; Alonso, Laura ; Badell, Isabel ; Fernández Navarro, José María ; Regueiro, Alexandra ; Plaza, Mercedes ; Pérez Hurtado, Jose María ; Benito, Ana ; Beléndez, Cristina ; Couselo, José Miguel ; Fuster, José Luis ; Díaz‐Almirón, Mariana ; Bueno, David ; Mozo, Yasmina ; Marsal, Julia ; Gómez López, Alicia ; Sisinni, Luisa ; Heredia, Cristina Díaz ; Díaz, Miguel Ángel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-a8aa5d2f4387a48975b6504bfcb0ba311869b4140eb2b30779e793983ae19f033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone Marrow Transplantation - methods</topic><topic>Bone Marrow Transplantation - mortality</topic><topic>CD19 antigen</topic><topic>CD3 antigen</topic><topic>CD34 antigen</topic><topic>CD45RA antigen</topic><topic>Child</topic><topic>Comparative analysis</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Graft Survival</topic><topic>Graft vs Host Disease - prevention & control</topic><topic>Graft-versus-host reaction</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic Stem Cell Transplantation - mortality</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Leukemia - mortality</topic><topic>Leukemia - therapy</topic><topic>Lymphocyte Depletion</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Minimal residual disease</topic><topic>Pediatrics</topic><topic>Pediatrics - methods</topic><topic>Peripheral blood</topic><topic>Prophylaxis</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Spain</topic><topic>Stem cell transplantation</topic><topic>Survival Analysis</topic><topic>T cell receptors</topic><topic>Transplantation, Haploidentical</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pérez‐Martínez, Antonio</creatorcontrib><creatorcontrib>Ferreras, Cristina</creatorcontrib><creatorcontrib>Pascual, Antonia</creatorcontrib><creatorcontrib>Gonzalez‐Vicent, Marta</creatorcontrib><creatorcontrib>Alonso, Laura</creatorcontrib><creatorcontrib>Badell, Isabel</creatorcontrib><creatorcontrib>Fernández Navarro, José María</creatorcontrib><creatorcontrib>Regueiro, Alexandra</creatorcontrib><creatorcontrib>Plaza, Mercedes</creatorcontrib><creatorcontrib>Pérez Hurtado, Jose María</creatorcontrib><creatorcontrib>Benito, Ana</creatorcontrib><creatorcontrib>Beléndez, Cristina</creatorcontrib><creatorcontrib>Couselo, José Miguel</creatorcontrib><creatorcontrib>Fuster, José Luis</creatorcontrib><creatorcontrib>Díaz‐Almirón, Mariana</creatorcontrib><creatorcontrib>Bueno, David</creatorcontrib><creatorcontrib>Mozo, Yasmina</creatorcontrib><creatorcontrib>Marsal, Julia</creatorcontrib><creatorcontrib>Gómez López, Alicia</creatorcontrib><creatorcontrib>Sisinni, Luisa</creatorcontrib><creatorcontrib>Heredia, Cristina Díaz</creatorcontrib><creatorcontrib>Díaz, Miguel Ángel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pérez‐Martínez, Antonio</au><au>Ferreras, Cristina</au><au>Pascual, Antonia</au><au>Gonzalez‐Vicent, Marta</au><au>Alonso, Laura</au><au>Badell, Isabel</au><au>Fernández Navarro, José María</au><au>Regueiro, Alexandra</au><au>Plaza, Mercedes</au><au>Pérez Hurtado, Jose María</au><au>Benito, Ana</au><au>Beléndez, Cristina</au><au>Couselo, José Miguel</au><au>Fuster, José Luis</au><au>Díaz‐Almirón, Mariana</au><au>Bueno, David</au><au>Mozo, Yasmina</au><au>Marsal, Julia</au><au>Gómez López, Alicia</au><au>Sisinni, Luisa</au><au>Heredia, Cristina Díaz</au><au>Díaz, Miguel Ángel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2020-01</date><risdate>2020</risdate><volume>95</volume><issue>1</issue><spage>28</spage><epage>37</epage><pages>28-37</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><abstract>A total of 192 pediatric patients, median age 8.6 years, with high‐risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo‐HSCT) using post‐transplantation cyclophosphamide (PT‐Cy), or ex vivo T cell‐depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers in Spain. Some 41 patients received an unmanipulated graft followed by PT‐Cy for graft‐vs‐host disease (GvHD) prophylaxis. A total of 151 patients were transplanted with CD3‐depleted peripheral blood stem cells (PBSCs) by either CD34+ selection, CD3+CD19+ depletion, TCRαβ+CD19+ depletion or CD45RA+ depletion, added to CD34+ selection for GvHD prophylaxis. The PBSCs were the only source in patients following ex vivo TCD haplo‐HSCT; bone marrow was the source in 9 of 41 patients following PT‐CY haplo‐HSCT. Engraftment was achieved in 91.3% of cases. A donor younger than 30 years, and the development of chronic GvHD were positive factors influencing survival, whereas positive minimal residual disease (MRD) before transplant and lymphoid disease were negative factors. The probability of relapse increased with lymphoid malignancies, a donor killer‐cell immunoglobulin‐like receptor (KIR) haplotype A and positive MRD pretransplant. No difference was found in overall survival, disease‐free survival or relapse incidence between the two platforms. Relapse is still of concern in both platforms, and it should be the focus of future efforts. In conclusion, both platforms for haplo‐HSCT were effective and could be utilized depending on the comfort level of the center.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>31625177</pmid><doi>10.1002/ajh.25661</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6436-9195</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2020-01, Vol.95 (1), p.28-37 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2307154203 |
| source | Wiley-Blackwell Journals; MEDLINE; Wiley Online Library Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Bone marrow Bone marrow transplantation Bone Marrow Transplantation - methods Bone Marrow Transplantation - mortality CD19 antigen CD3 antigen CD34 antigen CD45RA antigen Child Comparative analysis Cyclophosphamide Cyclophosphamide - therapeutic use Female Graft Survival Graft vs Host Disease - prevention & control Graft-versus-host reaction Hematologic Neoplasms - therapy Hematology Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - mortality Hematopoietic stem cells Humans Leukemia - mortality Leukemia - therapy Lymphocyte Depletion Lymphocytes T Male Minimal residual disease Pediatrics Pediatrics - methods Peripheral blood Prophylaxis Recurrence Retrospective Studies Spain Stem cell transplantation Survival Analysis T cell receptors Transplantation, Haploidentical Transplants & implants |
| title | Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A31%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Haploidentical%20transplantation%20in%20high%E2%80%90risk%20pediatric%20leukemia:%20A%20retrospective%20comparative%20analysis%20on%20behalf%20of%20the%20Spanish%20working%20Group%20for%20bone%20marrow%20transplantation%20in%20children%20(GETMON)%20and%20the%20Spanish%20Grupo%20for%20hematopoietic%20transplantation%20(GETH)&rft.jtitle=American%20journal%20of%20hematology&rft.au=P%C3%A9rez%E2%80%90Mart%C3%ADnez,%20Antonio&rft.date=2020-01&rft.volume=95&rft.issue=1&rft.spage=28&rft.epage=37&rft.pages=28-37&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.25661&rft_dat=%3Cproquest_cross%3E2323112597%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2323112597&rft_id=info:pmid/31625177&rfr_iscdi=true |